ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly mounjaro (tirzepatide — Type 2 diabetes & international obesity) — Worldwide revenue ($M) ($M)
Form 10-Q / 10-K Note 2, MD&A & Form 8-K Earnings Releases
Latest, FY2025
22,965
Period ended Dec 31, 2025
Change on a year earlier
+99.0%
11,540 in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Mounjaro (tirzepatide — Type 2 diabetes & international obesity) — Worldwide revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 22,965 | +99.0% | Form 10-K FY2025 (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 11,540 | +123.5% | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 5,163 | +970.1% | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 483 | – | Form 10-K FY2022 (filed 2023-02-22) ↗ |
Breakdown
What makes up mounjaro (tirzepatide — type 2 diabetes & international obesity) — worldwide revenue ($m)
Cite this data
StockData. (2026). Eli Lilly Mounjaro (tirzepatide — Type 2 diabetes & international obesity) — Worldwide revenue ($M) ($M), annual FY2022–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_mounjaro_ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.